Mavacamten

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mavacamten
DrugBank Accession Number
DB14921
Background

Mavacamten is under investigation in clinical trial NCT03442764 (A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 273.336
Monoisotopic: 273.147726864
Chemical Formula
C15H19N3O2
Synonyms
  • Mavacamten

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QX45B99R3J
CAS number
1642288-47-8
InChI Key
RLCLASQCAPXVLM-NSHDSACASA-N
InChI
InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
IUPAC Name
6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O

References

General References
Not Available
ChemSpider
57876199

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentObstructive Hypertrophic Cardiomyopathy1
3RecruitingTreatmentObstructive Hypertrophic Cardiomyopathy1
2Active Not RecruitingTreatmentHypertrophic Cardiomyopathy (HCM)1
2CompletedTreatmentNon-obstructive Hypertrophic Cardiomyopathy1
2RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
2, 3Enrolling by InvitationTreatmentHypertrophic Cardiomyopathy (HCM) / Non-obstructive Hypertrophic Cardiomyopathy / Obstructive Hypertrophic Cardiomyopathy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.226 mg/mLALOGPS
logP2.1ALOGPS
logP2.21ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)10.7ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.44 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity86.78 m3·mol-1ChemAxon
Polarizability29.92 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 14:35 / Updated on February 21, 2021 18:55